Skip to Main Content

Posters

Enhanced Cryopreservation of Therapeutically Relevant Cells

PDF · Published 2026-05-13 · 3 min read

Superior Performance of Recombinant Albumin and Its Role in Reducing DMSO Dependency

Author(s): Mark Stathos, PhD, Applications Scientist; Wren Michaels, PhD, Molecular Biology Scientist; Marcus Curl, Vice President of Product Applications
InVitria, Inc., USA

Reduced-DMSO cryopreservation workflows often compromise post-thaw viability, expansion, and functional cell attributes due to increased cellular stress during freeze/thaw. In a comparative study across T cells, mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs), InVitria® evaluated whether recombinant human serum albumin (rHSA) could improve cryopreservation performance relative to plasma-derived HSA (pHSA) and albumin-free controls across 2%, 5%, and 10% DMSO formulations. Post-thaw recovery, apoptosis, proliferation, viability, and pluripotency were assessed alongside analytical characterization of albumin aggregation and Cys34 redox state. Recombinant albumin supported maintained or improved post-thaw performance at reduced DMSO concentrations while demonstrating significantly lower aggregate burden and improved redox consistency compared to plasma-derived material.

Key Findings

The study established several findings with direct implications for cell therapy cryopreservation and manufacturing workflows:

  • Recombinant albumin supported reduced-DMSO cryopreservation while maintaining or improving post-thaw recovery across T cells, MSCs, and iPSCs
  • In T cells, 5% DMSO with rHSA matched the expansion performance of conventional 10% DMSO formulations
  • In MSCs, rHSA reduced apoptosis and preserved post-thaw viability under low-DMSO conditions
  • In iPSCs, rHSA improved recovery and expansion while preserving pluripotency markers at reduced DMSO concentrations
  • Analytical characterization showed recombinant albumin contained substantially lower aggregate levels and more consistent Cys34 redox profiles than plasma-derived HSA

Why Cryopreservation Formulations Matter

Cryopreservation is a critical step in cell therapy manufacturing, enabling cell storage, transport, process flexibility, and final drug product preparation. However, conventional cryopreservation systems frequently rely on high concentrations of dimethyl sulfoxide (DMSO), which is associated with cellular toxicity, apoptosis, altered phenotype, and downstream patient safety concerns.

Albumin is commonly incorporated into cryopreservation formulations because it provides multiple protective functions during freeze/thaw stress. Albumin reduces ice crystal formation by interacting with water molecules, mitigates oxidative stress through antioxidant activity, and helps preserve membrane integrity and cellular viability during freezing and thawing.

Plasma-derived human serum albumin has historically been used for this purpose, but donor-derived material introduces structural heterogeneity, oxidation, aggregate burden, and lot-to-lot variability that may affect reproducibility in sensitive workflows. Recombinant albumin eliminates many of these liabilities while maintaining the functional benefits associated with albumin supplementation.

Study Design

T cells, MSCs, and iPSCs were expanded and cryopreserved using formulations containing 2%, 5%, or 10% DMSO combined with recombinant human serum albumin, plasma-derived HSA, or no albumin controls. Following thaw, cells were monitored using live-cell imaging systems to evaluate proliferation, viability, apoptosis, and functional recovery over multiple days in culture.

Additional analytical characterization compared recombinant and plasma-derived albumin using native capillary electrophoresis to quantify aggregate burden and reverse-phase HPLC to assess Cys34 redox state and oxidative status.

Results

Improved Post-Thaw T Cell Expansion at Reduced DMSO

Recombinant albumin improved post-thaw T cell expansion across multiple DMSO concentrations. Notably, formulations containing 5% DMSO with rHSA achieved expansion performance comparable to standard 10% DMSO conditions, supporting equivalent growth with reduced cryoprotectant exposure. See the full Application Note.

Reduced MSC Apoptosis and Maintained Viability

In MSC workflows, recombinant albumin reduced apoptosis and restored post-thaw viability under reduced-DMSO conditions. Albumin-free controls showed substantially lower viability and increased apoptosis, particularly at lower DMSO concentrations. See the full Application Note.

Enhanced iPSC Recovery and Preservation of Pluripotency

In iPSCs, recombinant albumin improved post-thaw recovery and expansion while preserving pluripotency markers under reduced-DMSO conditions. Formulations containing rHSA outperformed albumin-free controls and matched or exceeded plasma-derived HSA performance across multiple endpoints. See the full Application Note.

Structural Homogeneity Supports Functional Performance

Analytical characterization demonstrated that recombinant albumin contained substantially lower aggregate levels and more reduced Cys34 species compared to plasma-derived HSA. Recombinant albumin also demonstrated significantly lower lot-to-lot variability across tested batches, supporting more predictable cryopreservation performance. See the full Application Note.

Conclusion

Recombinant human serum albumin supports reduced-DMSO cryopreservation while maintaining or improving post-thaw viability, expansion, and functional cell attributes across multiple therapeutically relevant cell types. By combining lower aggregate burden, improved redox consistency, and animal-origin-free production, recombinant albumin provides a more controlled and reproducible alternative to plasma-derived HSA for advanced cell therapy manufacturing workflows.

Download the Poster

Download the full scientific poster presentation: Enhanced Cryopreservation of Therapeutically Relevant Cells: Superior Performance of Recombinant Albumin and Its Role in Reducing DMSO Dependency.


The following content is gated. Please, subscribe to open access to it.

REFERENCES

  1. Alfano, R., Pennybaker, A., & Pezoa, S. A. (2021). Recent advances of chemical definition of cell culture media and excipients for virus and viral vector manufacturing: A review. Journal of Bioprocessing & Biotechniques, 11(2), Article 482.
    https://www.hilarispublisher.com/open-access/recent-advances-of-chemical-definition-of-cell-culture-media-and-excipients-for-virus-and-viral-vector-manufacturing-a-review-69449.html
  2. Bailey-Schmidt, T., Saunders, C. V., George, C. E., Scorer, T. G., McCallum, L. M. R., & Madgett, T. E. (2026). Serum-derived albumin as a cryoprotective agent for the long-term storage of red blood cells: A preliminary examination. Transfusion, 66(Suppl. 1), S310–S320. https://doi.org/10.1111/trf.70192
  3. Bandeira, V., Peixoto, C., Rodrigues, A. F., Cruz, P. E., Alves, P. M., Coroadinha, A. S., & Carrondo, M. J. T. (2012). Downstream processing of lentiviral vectors: Releasing bottlenecks. Human Gene Therapy Methods, 23(4), 255–263.
    https://doi.org/10.1089/hgtb.2012.059
  4. BioLife Solutions, Inc. (2019). CryoStor® CS2; CS5; CS10 safety data sheet. BioLife Solutions. https://www.biolifesolutions.com/wp-content/uploads/2022/11/6035_01-CryoStor-CS2-CS5-CS10-Safety-Data-Sheet-EU.pdf
  5. Brandau, D. T., Jones, L. S., Wiethoff, C. M., Rexroad, J., & Middaugh, C. R. (2003). Thermal stability of vaccines. Journal of Pharmaceutical Sciences, 92(2), 218–231. https://doi.org/10.1002/jps.10296
  6. Burke, C. W., & Volkin, D. B. (2001). Stabilized viral formulations (U.S. Patent No. 6,210,683 B1). U.S. Patent and Trademark Office. https://patents.google.com/patent/US6210683B1/en
  7. Carmo, M., Alves, A., Rodrigues, A. F., Coroadinha, A. S., Carrondo, M. J. T., Alves, P. M., & Cruz, P. E. (2009). Stabilization of gammaretroviral and lentiviral vectors: From production to gene transfer. The Journal of Gene Medicine, 11(8), 670–678. https://doi.org/10.1002/jgm.135
  8. Comisel, R. M., Faulkner, P., Butler, M., & Gagnon, P. (2021). Lentiviral vector bioprocess economics for cell and gene therapy commercialization. Biochemical Engineering Journal, 168, Article 107868. https://doi.org/10.1016/j.bej.2020.107868
  9. Eilts, F., Harsy, Y. M. J., Lothert, K., Pagallies, F., Amann, R., & Wolff, M. W. (2023). An investigation of excipients for a stable Orf viral vector formulation. Virus Research, 336, Article 199213. https://doi.org/10.1016/j.virusres.2023.199213
  10. European Medicines Agency. (2019). Ervebo: Ebola Zaire vaccine assessment report (EMA/606159/2019). https://www.ema.europa.eu/en/medicines/human/EPAR/ervebo
  11. Finn, T. E., Nunez, A. C., Sunde, M., & Easterbrook-Smith, S. B. (2012). Serum albumin prevents protein aggregation and amyloid formation and retains chaperone-like activity in the presence of physiological ligands. Journal of Biological Chemistry, 287(25), 21530–21540. https://doi.org/10.1074/jbc.M112.372961
  12. Hamann, A., & Stathos, M. (2025a). Enhanced cryopreservation of T cells using Optibumin®, recombinant human serum albumin (rHSA) [Application note]. InVitria, Inc. https://invitria.com/resources/enhanced-cryopreservation-of-t-cells-using-optibumin-rhsa/
  13. Hamann, A., & Stathos, M. (2025b). Low-DMSO cryopreservation of MSCs with Optibumin 25 recombinant albumin [Application note]. InVitria, Inc. https://invitria.com/resources/low-dmso-cryopreservation-of-mscs-with-optibumin-25-recombinant-albumin/
  14. Hansen, L. J. J., Daoussi, R., Vervaet, C., Remon, J.-P., & De Beer, T. R. M. (2015). Freeze-drying of live virus vaccines: A review. Vaccine, 33(42), 5507–5519. https://doi.org/10.1016/j.vaccine.2015.08.085
  15. Khan, M. D. F. H., Wagner, C. E., & Kamen, A. A. (2024). Development of long-term stability of enveloped rVSV viral vector expressing SARS-CoV-2 antigen using a DOE-guided approach. Vaccines, 12(11), Article 1240. https://doi.org/10.3390/vaccines12111240
  16. Kumru, O. S., Wang, Y., Gombotz, C. W. R., Kelley-Clarke, B., Cieplak, W., Kim, T., Joshi, S. B., & Volkin, D. B. (2018). Physical characterization and stabilization of a lentiviral vector against adsorption and freeze-thaw. Journal of Pharmaceutical Sciences, 107(11), 2764–2774. https://doi.org/10.1016/j.xphs.2018.07.010
  17. Leslie, S. B., Israeli, E., Lighthart, B., Crowe, J. H., & Crowe, L. M. (1995). Trehalose and sucrose protect both membranes and proteins in intact bacteria during drying. Applied and Environmental Microbiology, 61(10), 3592–3597. https://doi.org/10.1128/aem.61.10.3592-3597.1995
  18. Lu, J. R., Su, T. J., & Penfold, J. (1999). Adsorption of serum albumins at the air/water interface. Langmuir, 15(20), 6975–6983. https://doi.org/10.1021/la990131h
  19. Luostarinen, A., Kailaanmäki, A., Turkki, V., Köylijärvi, M., Käyhty, P., Leinonen, H., Albers-Skirdenko, V., Lipponen, E., Ylä-Herttuala, S., Kaartinen, T., Lesch, H. P., & Kekarainen, T. (2024). Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing. Cytotherapy, 26(10), 1084–1094. https://doi.org/10.1016/j.jcyt.2024.04.002
  20. Martínez-Molina, E., Chocarro-Wrona, C., Martínez-Moreno, D., Marchal, J. A., & Boulaiz, H. (2020). Large-scale production of lentiviral vectors: Current perspectives and challenges. Pharmaceutics, 12(11), Article 1051. https://doi.org/10.3390/pharmaceutics12111051
  21. Mazur, P., & Rigopoulos, N. (1983). Contributions of unfrozen fraction and of salt concentration to the survival of slowly frozen human erythrocytes: Influence of warming rate. Cryobiology, 20(3), 274–289. https://doi.org/10.1016/0011-2240(83)90016-0
  22. Murray, A., Kilbride, P., & Gibson, M. I. (2024). Trehalose in cryopreservation: Applications, mechanisms and intracellular delivery opportunities. RSC Medicinal Chemistry, 15, 2980–2995. https://doi.org/10.1039/D4MD00174E
  23. Pastorino, B., Baronti, C., Gould, E. A., Charrel, R. N., & de Lamballerie, X. (2015). Effect of chemical stabilizers on the thermostability and Infectivity of a representative panel of freeze dried viruses. PLOS ONE, 10(4), Article e0118963. https://doi.org/10.1371/journal.pone.0118963
  24. Perry, C., Mujahid, N., Takeuchi, Y., & Rayat, A. C. M. E. (2024). Insights into product and process related challenges of lentiviral vector bioprocessing. Biotechnology and Bioengineering, 121(8), 2466–2481. https://doi.org/10.1002/bit.28498
  25. Przybyłek, M., Bełdowski, P., Ledziński, D., Lutowski, Z., Mazurkiewicz, A., Raczyński, P., Dedinaite, A., & Claesson, P. M. (2024). Molecular insights into the interactions between human serum albumin and phospholipid membranes. Applied Sciences, 14(24), Article 11753. https://doi.org/10.3390/app142411753
  26. Puri, M., Morar-Mitrica, S., Crotts, G., & Nesta, D. (2015). Evaluating freeze-thaw processes in biopharmaceutical development: Small-scale study designs. BioProcess International, 13(1), 34–45. https://www.bioprocessintl.com/fill-finish/evaluating-freeze-thaw-processes-in-biopharmaceutical-development-small-scale-study-designs
  27. Quinn, K. S. (2020). Novel or not? Our inadvertent journey filing a novel excipient [Webinar presentation]. Merck & Co.; IPEC-Americas Excipient World Webinar Series. https://education.ipecamericas.org/courses/30181
  28. Singh, S. K., Kolhe, P., Wang, W., & Nema, S. (2009). Large-scale freezing of biologics: A practitioner’s review, part 2: Practical advice. BioProcess International, 7(10), 34–42. https://www.bioprocessintl.com/fill-finish/large-scale-freezing-of-biologics
  29. Stathos, M. (2025). Improved iPSC cryopreservation with Optibumin 25 [Application note]. InVitria, Inc. https://invitria.com/resources/improved-ipsc-cryopreservation-with-optibumin-25/
  30. Stathos, M., Michaels, W., & Weber, J. (2026). Preserving infectious lentivirus titer by pre-coating sterile filters with recombinant albumin [Application note]. InVitria, Inc.  https://invitria.com/resources/preserving-lentiviral-titer-during-sterile-filtration-using-recombinant-albumin/
  31. Stibbs, H. H., Lendon, K., McDonald, D., McLachlan, R., Tapping, R. I., & Schaffer, D. V. (2024). Lentiviral vector adsorption and recovery during downstream processing: Mechanisms and mitigation strategies. Molecular Therapy: Methods & Clinical Development, 32, 101209.  https://doi.org/10.1016/j.omtm.2024.101209
  32. Taverna, M., Marie, A.-L., Mira, J.-P., & Guidet, B. (2013). Specific antioxidant properties of human serum albumin. Annals of Intensive Care, 3, Article 4. https://doi.org/10.1186/2110-5820-3-4
  33. Thakur, R., Das, A., & Chakraborty, A. (2014). Interaction of human serum albumin with liposomes of saturated and unsaturated lipids with different phase transition temperatures: A spectroscopic investigation by membrane probe PRODAN. RSC Advances, 4, 14335–14347. https://doi.org/10.1039/C4RA01214C
  34. Twomey, A., Less, R., Kurata, K., Takamatsu, H., & Aksan, A. (2013). In situ spectroscopic quantification of protein-ice interactions. The Journal of Physical Chemistry B, 117(26), 7889–7897. https://doi.org/10.1021/jp403267x
  35. U.S. Food and Drug Administration. (2026). Package insert: ERVEBO® (Ebola Zaire Vaccine, Live), injectable suspension, for intramuscular use. Merck Sharp & Dohme LLC. https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert-ERVEBO_1.pdf
  36. Valkama, A. J., Oruetxebarria, I., Lipponen, E. M., Leinonen, H. M., Käyhty, P., Hynynen, H., Turkki, V., Malinen, J., Miinalainen, T., Heikura, T., Parker, N. R., Ylä-Herttuala, S., & Lesch, H. P. (2020). Development of large-scale downstream processing for lentiviral vectors. Molecular Therapy: Methods & Clinical Development, 17, 717–730. https://doi.org/10.1016/j.omtm.2020.03.025
  37. Wiggan, O., Livengood, J. A., Silengo, S. J., Kinney, R. M., Osorio, J. E., Huang, C. Y.-H., & Stinchcomb, D. T. (2011). Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines. Vaccine, 29(43), 7456–7462. https://doi.org/10.1016/j.vaccine.2011.07.054
  38. Zhai, S., Hansen, R. K., Taylor, R., Skepper, J. N., Sanches, R., & Slater, N. K. H. (2004). Effect of freezing rates and excipients on the infectivity of a live viral vaccine during lyophilization. Biotechnology Progress, 20(4), 1113–1120.
    https://doi.org/10.1021/bp034362x

More resources

Keep reading.

Talk to a Scientist

See how rHSA performs in your media.

Send us your cell line and formulation and we will help you design a side-by-side evaluation against your current albumin.